Merck & Co. is buying the developer of an experimental antiviral drug designed to prevent the flu, as the drugmaker aims to counter sales cliffs for two of its biggest drugs. Merck has been vocal ...

Merck shares began peeling back in early 2024, mostly on concerns about looming patent expirations for its breadwinning drug. The trading crowd changed its collective mind a couple months ago, sending ...

Halozyme HALO0.47%increase; green up pointing triangle was granted a preliminary injunction that would prevent Merck MRK-0.41%decrease; red down pointing triangle & Co. from distributing a formulation ...

Ed Silverman, a senior writer and Pharmalot columnist at STAT, has been covering the pharmaceutical industry for nearly three decades. He is also the author of the morning Pharmalittle newsletter and ...

That term has become the industry shorthand for assuring people nervous about AI’s increasing foothold in healthcare. There’s always someone watching over what AI does. We are there to make sure ...

AstraZeneca AZN and Merck MRK are both major global pharmaceutical companies with diversified drug portfolios. While Merck is a U.S.-based company, AstraZeneca’s headquarters are in Cambridge, UK.

Merck (MRK)’s stock surged by 41% over the past six months, driven not significantly by revenue, but rather by increased profits and heightened investor confidence. Following crucial Q3 earnings ...

Merck's newest acquisition grants it access to a highly promising medicine. That could help it overcome the challenges its two biggest franchises are facing. Merck has other things going its way, ...

Positive results from a proof-of-concept study evaluating Merck’s Winrevair pave the way for further study of the activin signaling inhibitor as a potential treatment for a subset of heart failure ...

Merck & Co. has agreed to acquire Cidara Therapeutics for approximately $9.2 billion, the companies said, in a deal designed to bolster the buyer’s antiviral pipeline with a Phase III drug designed to ...

Nov 14 (Reuters) - Merck (MRK.N), opens new tab will acquire Cidara Therapeutics (CDTX.O), opens new tab in a nearly $9.2 billion deal, gaining access to an experimental flu drug in its effort to ...